Financial Performance - For the six months ended June 30, 2021, the company reported revenue of RMB 301,326,000, an increase of 5.8% compared to RMB 285,644,000 for the same period in 2020[4] - Gross profit for the same period was RMB 239,108,000, a decrease of 1.8% from RMB 243,274,000 year-on-year[4] - Operating profit increased to RMB 62,694,000, up 1.4% from RMB 61,844,000 in the previous year[4] - Profit attributable to shareholders was RMB 48,977,000, down 5.5% from RMB 51,686,000 in the same period last year[4] - Basic earnings per share for the six months was 8.74 cents, compared to 9.23 cents in the previous year[4] - The operating profit for the six months ended June 30, 2021, was RMB 48,977,000, down from RMB 51,686,000 in the same period of 2020, reflecting a decrease of approximately 5.23%[20] - The basic earnings per share for the six months ended June 30, 2021, was RMB 0.087, down from RMB 0.092 in the same period of 2020, indicating a decrease of approximately 5.43%[20] - The gross margin for the six months ended June 30, 2021, was approximately 79.4%, down 5.9% from 85.3% in the same period of 2020[45] Assets and Liabilities - Total non-current assets as of June 30, 2021, amounted to RMB 1,090,544,000, an increase from RMB 996,616,000 at the end of 2020[6] - Current assets totaled RMB 803,799,000, slightly down from RMB 807,887,000 at the end of 2020[6] - Current liabilities increased to RMB 452,222,000 from RMB 415,435,000 at the end of 2020[6] - The company's net asset value as of June 30, 2021, was RMB 1,394,459,000, up from RMB 1,345,482,000 at the end of 2020[8] - The total assets of the company as of June 30, 2021, were RMB 167,745,000, compared to RMB 169,969,000 as of December 31, 2020, showing a decrease of about 1.31%[24] Dividends - The company did not declare any dividends for the period[4] - The company did not declare an interim dividend for the six months ended June 30, 2021, consistent with the previous year[21] - The company proposed a special dividend of RMB 0.0275 per share, subject to shareholder approval[44] Tax and Expenses - The income tax expense for the six months ended June 30, 2021, was RMB 13,526,000, compared to RMB 9,481,000 in the same period of 2020, which is an increase of about 42.4%[19] - The company’s depreciation expense for the six months ended June 30, 2021, was RMB 11,441,000, compared to RMB 10,114,000 in the same period of 2020, representing an increase of approximately 13.09%[17] - Sales expenses accounted for 43% of revenue for the six months ended June 30, 2021, a decrease from 44% in the same period of 2020[45] Shareholder Information - As of June 30, 2021, Mr. Zhang Hong holds 101,937,000 shares, representing 26.29% of domestic shares and 18.19% of total registered capital[56] - Huinan County Caiyuan Investment holds 81,975,000 shares, accounting for 21.14% of domestic shares and 14.63% of total registered capital[60] - The company did not repurchase, sell, or redeem any of its listed shares during the six-month period ending June 30, 2021[69] Corporate Governance - The audit committee consists of three independent non-executive directors, responsible for reviewing the financial procedures and internal control systems of the group[67] - The company has adopted a code of conduct for securities trading that meets or exceeds the standards set by GEM Listing Rules[64] - No directors or senior management were granted or exercised any rights to acquire benefits through the purchase of the company's shares or bonds during the period[58] - The company reported no knowledge of any other individuals holding interests or short positions in the company's shares and related securities, aside from those disclosed[61] - The company has not established any arrangements allowing directors or senior management to acquire rights in any other corporations[58] - The company believes that having an executive chairman is in the best interest of the group, as it benefits from the chairman's deep understanding of the business[65] Workforce - The company employed 951 staff members as of June 30, 2021, an increase from 856 staff members on June 30, 2020[68] Research and Development - The company plans to develop 16 new products in the areas of generic drug research and production, enhancing its R&D capabilities and market competitiveness[48] - The company upgraded production facilities to increase production capacity and meet market demand[46] Risk Management - The company believes that foreign exchange risk has minimal impact on its operations[49] - The company maintained a capital debt ratio of approximately 0% as of June 30, 2021, with no short-term bank borrowings[51]
吉林长龙药业(08049) - 2021 - 中期财报